APOE and Alzheimer disease: Here, we found that within the non‐amnestic AD cohort, there were no age at onset differences between APOE ɛ4 positive carriers and negative carriers, whereas in the remaining EOAD and LOAD, the interaction of APOE ɛ4 with novel factors was significant (p = 0.013), with APOE ɛ4 positive carriers showing first symptoms on average 3 years before those who were APOE ɛ4 negative (Figure S1 in supporting information).